Abstract
This review describes the use of lipid-based nanocarriers (LNCs) for the parenteral delivery of pharmaceutical actives. Firstly, the two generations of LNCs, namely solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), are explained in terms of preparation, characterization and stability. Although the use of LNCs through parenteral administration has shown many benefits, their use is limited by opsonization, an immune process that causes their short half-life (3-5 min). Therefore, many strategies are discussed to realize “stealth” systems suitable for parenteral administration. The requirements and applications of parenteral lipid nanoparticles are reviewed for the delivery of natural compounds, synthetic drugs and genetic materials. Recently, the latter application has been of remarkable interest due to the numerous benefits of mRNA vaccines to fight the Covid-19 pandemic.
Keywords: Lipid nanoparticles, phytocompounds, synthetic drugs, parenteral drug delivery, mRNA vaccine, Covid-19.
Current Medicinal Chemistry
Title:Applications of Lipid-based Nanocarriers for Parenteral Drug Delivery
Volume: 29 Issue: 24
Author(s): Debora Santonocito*Carmelo Puglia
Affiliation:
- Department of Drug and Health Science, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy
Keywords: Lipid nanoparticles, phytocompounds, synthetic drugs, parenteral drug delivery, mRNA vaccine, Covid-19.
Abstract: This review describes the use of lipid-based nanocarriers (LNCs) for the parenteral delivery of pharmaceutical actives. Firstly, the two generations of LNCs, namely solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), are explained in terms of preparation, characterization and stability. Although the use of LNCs through parenteral administration has shown many benefits, their use is limited by opsonization, an immune process that causes their short half-life (3-5 min). Therefore, many strategies are discussed to realize “stealth” systems suitable for parenteral administration. The requirements and applications of parenteral lipid nanoparticles are reviewed for the delivery of natural compounds, synthetic drugs and genetic materials. Recently, the latter application has been of remarkable interest due to the numerous benefits of mRNA vaccines to fight the Covid-19 pandemic.
Export Options
About this article
Cite this article as:
Santonocito Debora*, Puglia Carmelo, Applications of Lipid-based Nanocarriers for Parenteral Drug Delivery, Current Medicinal Chemistry 2022; 29 (24) . https://dx.doi.org/10.2174/0929867329666220104111949
DOI https://dx.doi.org/10.2174/0929867329666220104111949 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Physiological Functions of NO-Sensitive Guanylyl Cyclase Isoforms
Current Medicinal Chemistry Treating Asthma as a Neuroelectrical Disorder
Inflammation & Allergy - Drug Targets (Discontinued) The Role and Modulation of the Oxidative Balance in Pregnancy
Current Pharmaceutical Design Hypertension in Patients with Severe Aortic Stenosis: Emphasis on Antihypertensive Treatment and the Risk of Syncope
Current Hypertension Reviews Depressive Illness and Emotional Learning
Current Medical Imaging Novel Nanostructured Polymeric Carriers to Enable Drug Delivery for Cardiovascular Diseases
Current Pharmaceutical Design Treatment of Obesity: Should We Target the Individual or Society?
Current Pharmaceutical Design Why and how do Microbubbles Enhance the Effectiveness of Diagnostic and Therapeutic Interventions in Cerebrovascular Disease?
Current Pharmaceutical Design Investigational Positive Inotropic Agents for Acute Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Magnesium and Anaesthesia
Current Drug Targets The Effects of Dietary Supplements that Overactivate the Nrf2/ARE System
Current Medicinal Chemistry Increased Neuronal Injury in Clock Gene Per-1 Deficient-Mice after Cerebral Ischemia
Current Neurovascular Research Myocardial Quantitative Analysis in Physiological and Pathological Ventricular Hypertrophy: The Increasing Role of Doppler Myocardial Imaging
Current Cardiology Reviews Repeated Restraint and Nerve Growth Factor Administration in Male and Female Mice: Effect on Sympathetic and Cardiovascular Mediators of the Stress Response
Current Neurovascular Research Expression Microarray Proteomics and the Search for Cancer Biomarkers
Current Genomics Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Early-Life Stress and Psychiatric Disorders: Epidemiology, Neurobiology and Innovative Pharmacological Targets
Current Pharmaceutical Design G Protein-Coupled Receptor Fusion Proteins in Drug Discovery
Current Pharmaceutical Design Editorial (Thematic Issues: Advances in Developmental and Reproductive Toxicology)
Current Pharmaceutical Design Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome
Current Pharmaceutical Design